Skip to main content
$270.46 -3.59 (-1.31%)
Market Cap
$71.53B
Shares
264.24M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$274.05 Open$276.27 Day$272.08–276.98 52W$235.50–310.19 Avg vol 30d1.8M Short int6.2M · 2.3% float · 4.3d Short vol34% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 29, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 16.5 · calm Equity put/call 0.46
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −2%
      below
      Price vs 50-day avg −4%
      below
      RSI (14) 40
      neutral
      MACD trend Negative
      52-week position 52%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −4%
      trailing
      6-month return −4%
      trailing
      YTD return +1%
      this year
      Relative strength −15%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $286 › 200d $280 — 50d above 200d
      Institutional flow Distributing
      840 of 1,656 funds reported for Jun 30 · net -558.2K sh shares · +70 new
      Insider flow Distributing
      Net -$59.4M over 90 days · 100% sells
      Short interest Falling
      2.34% of float · ▼ -0.8% MoM · 4.3 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      1,656 holders — mid 3-yr range
      Squeeze score 50
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +11%
      Y/Y
      EPS growth +83%
      Y/Y
      Free cash flow $8.6B
      Valuation P/E 11.2
      below peers
      Buyback $3.2B
      authorized
      Balance sheet $32.4B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 32%
      annualized · 1-yr
      Max drawdown −21%
      past year
      ATR 3.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 30, 2026
      Adjusted income from operations per share · 2026 outlook Non-GAAP Initiated at least $30.45

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 6 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −2% Neutral
      Price vs 50-day avg
      −4% Neutral
      RSI (14)
      40 Neutral
      MACD trend
      Negative Bearish
      52-week position
      52% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $286 › 200d $280 — 50d above 200d
      Institutional flow Distributing
      840 of 1,656 funds reported for Jun 30 · net -558.2K sh shares · +70 new
      Insider flow Distributing
      Net -$59.4M over 90 days · 100% sells
      Short interest Falling
      2.34% of float · ▼ -0.8% MoM · 4.3 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      1,656 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $236 Now $274 · 52% 52-wk high $310
      vs 200-day avg -2% vs 50-day avg -4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Cigna Healthcare MCR 84.5% second quarter 2026
      debt-to-capitalization ratio 42.3% March 31, 2026
      Adjusted Income from Operations non-GAAP $8,014M Year Ended December 31, 2025
      GAAP → non-GAAP reconciliation
      GAAP Shareholders' Net Income $1,234M
      +$104M Net Investment (Gains) Losses
      +$327M Amortization of Acquired Intangible Assets
      +$483M Special Items
      = Adjusted Income from Operations $2,148M
      Adjusted Income from Operations, per share non-GAAP $29.84 Year Ended December 31, 2025
      Adjusted Revenues non-GAAP $274,651M Year Ended December 31, 2025
      Shares repurchased 11.9M Year Ended December 31, 2025

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Healthcare Plans — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CI
      Cigna Group
      this stock
      $71.53B +0.7% +11.2% 11.2 2.3%
      UNH
      Unitedhealth Group Inc
      $377.21B +25.1% +11.8% 31.3 1.9%
      CVS
      CVS HEALTH Corp
      $127.47B +34.7% +10.9% 26.3 1.5%
      ELV
      Elevance Health, Inc.
      $84.83B +8.9% +9.4% 17.3 2.8%
      HUM
      Humana Inc
      $44.03B +42.5% +10.1% 39.1 3.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      1,690
      % held
      88.4%
      Reported
      840 of 1,656
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,019
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      6.2M
      Days to cover
      4.3d
      Change
      -47.8K sh
      View
      Short Volume
      Short vol %
      34%
      As of
      Aug 5, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      100
      Value
      $28.8K
      As of
      Jul 6, 2026
      View
      Off-Exchange
      Off-exchange %
      40.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$59.4M
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 27, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $274.9B
      Net income (FY)
      $6.0B
      EPS diluted
      $22.18
      View
      Buybacks
      Authorized
      $3.2B
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $5.4M
      Shares
      19.4K
      Filed
      Aug 4, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View
      Investor Relations
      Latest news
      Cigna Named Corporate Sustainabil…
      Published
      Dec 19, 2022
      View

      Performance

      5D 20D 120D MTD YTD
      CI -9.0% -4.4% -3.7% -1.8% +0.7%
      SPY +4.1% +3.2% +11.4% +3.3% +13.1%
      vs SPY -13.1% -7.6% -15.1% -5.0% -12.4%

      Capital returns

      Latest dividend
      $1.56 / share · ex Jun 4, 2026
      Raised 3.3%
      Paid (TTM)
      $6.14 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.24%
      Buyback program · as of Feb 15, 2024
      Authorized
      $3.20B
      Spent (derived)
      Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1739940 CUSIP 125523100 13F (30d) 825 filings 797 filers Visit website Investor relations